The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

The European Commission approval was based on results showing the immunotherapy regimen improved event-free survival in a Phase III trial.

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Clinical results have revealed the effect of laser tinib, a third-generation EGFR targeted treatment, on atypical EGFR gene ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Ideaya Biosciences, Inc. progresses trials for uveal melanoma and solid tumors, with key upcoming data milestones. Click for ...

Biotech company AbbVie (ABBV) said on Wednesday that the U.S. Food and Drug Administration has approved Emrelis medicine for ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...